Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on November 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a transaction involving the company's stock on November 1, 2024.
• McCourt exercised a non-qualified stock option to acquire 1,000 shares of Regeneron common stock at an exercise price of $381.40.
• Simultaneously, McCourt sold 1,000 shares of Regeneron common stock at a price of $844.61 per share.
• These transactions were executed under a pre-arranged trading plan compliant with Rule 10b5-1(c), which was adopted on February 13, 2024.
• Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
• McCourt also holds 6,000 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions under a pre-arranged plan, suggesting no particular concern or excitement about the company's prospects.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common and legal practice for corporate insiders to manage their stock holdings and avoid accusations of insider trading.

Industry Context

Insider transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects. The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• The exercise of stock options and subsequent sale of shares by executives is a common practice across the pharmaceutical industry.
• Companies like Amgen, Pfizer, and Johnson & Johnson also see similar insider transactions regularly.
• The use of 10b5-1 plans is widespread among executives at these companies to manage their stock holdings in a compliant manner.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on shareholders, as they are part of a pre-arranged trading plan.
• Employees may view the transactions as a standard part of executive compensation.

Key Dates